Clozapine reduces mortality in treatment-resistant schizophrenia

Psychiatrists in London have found that clozapine is associated with a 40% reduction in mortality in people with treatment-resistant schizophrenia.

Their analysis of an historical cohort of 1,025 patients with a diagnosis of treatment-resistant schizophrenia between 2008 and 2016 showed that, after controlling for potential confounders (sociodemographics, clinical monitoring, mental and physical illness severity and functional status), the hazard ratio for all-cause mortality among those treated with clozapine compared with controls was 0.61 (CI95% 0.38 – 0.97, p=0.04).

The authors note that, although clozapine has been shown to reduce mortality in people with schizophrenia overall, the evidence of its impact exclusively in people with treatment-resistant schizophrenia was previously inconclusive.

Web design and marketing agency Leamington Spa